Affiliations: [a] Department of Experimental Medicine, University of Perugia, Perugia, Italy | [b] Department of Medical-Surgical Specialties and Public Health, Public Health Division, University of Perugia, Perugia, Italy | [c] Department of Medical-Surgical Specialties and Public Health, Division of Urology and Andrology, University of Perugia, Perugia, Italy
Correspondence:
[*]
Corresponding author: Ettore Mearini, Department of Medical-Surgical Specialties and Public Health, Division of Urology and Andrology, University of Perugia, Perugia, Italy. Tel./Fax: +39 075 5724890; E-mail: [email protected].
Note: [1]
Vincenzo N. Talesa and Cinzia Antognelli contributed equally to this study.
Abstract: Prostate cancer (PCa) is a heterogeneous, multifactorial and multifocal disease. Therefore, the search for a combination of assays using a panel of tumor markers is fundamental for a more precise and reliable diagnosis. In the present study we investigated the diagnostic value of five different genes, associated with PCa carcinogenesis, encoding for prostate-specific membrane antigen (PSMA), serine protease Hepsin, PCa antigen 3 (PCA3), UDP-N-acetyl-α-D-galatosamine transferase (GalNAC-T3) and prostate-specific antigen (PSA). Forty-four patients, with previously untreated, histologically verified PCa and forty-six patients with benign prostatic hyperplasia (BPH) were enrolled in this study. Absolute concentration of the transcript levels of each gene was calculated by quantitative Real-Time PCR analysis in urine sediments of men suffering from PCa or BPH after prostatic massage. The diagnostic value of a concomitant examination of these markers was evaluated by logistic regression analysis. We demonstrated that the diagnostic potential of the combined urinary PSA and PSMA level was significantly better than that of each singularly considered marker, including total serum PSA, the present gold standard test for PCa diagnosis.
Keywords: PCA3/DD3, PSMA, PSA, panel of urinary biomarkers, prostate cancer
